Figure 3.

The Knockdown of MAGEA3 Reduces the Resistance of HepG2 Cells to Cisplatin

(A) CCK-8 assay showing viability and the IC₅₀ of HepG2 cells transfected with mock, si-NC, or si-MAGEA3 upon treatment with cisplatin at different concentrations. (B) The mRNA levels of MRP2, MRP3, and MDR-1 in HepG2 cells transfected with si-MAGEA3 upon cisplatin treatment determined by qRT-PCR. (C) The protein levels of MRP2, MRP3, and MDR-1 in HepG2 cells transfected with si-MAGEA3 upon cisplatin treatment measured using western blot analysis. (D) ALB content in the supernatant of HepG2 cells in response to si-MAGEA3 transfection detected by ELISA. Measurement data were expressed as mean ± SD. The comparisons among multiple groups were assessed with one-way ANOVA, followed by Tukey’s post hoc test. Each experiment was repeated three times. *p < 0.05 versus the mock- or si-NC-transfected cells.